Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

GK, Wilcock; S, Gauthier; GB, Frisoni; GB, Frisoni; J, Jia; JH, Hardlund; HJ, Moebius; P, Bentham; KA, Kook; BO, Schelter; DJ, Wischik; CS, Davis; RT, Staff; V, Vuksanovic; T, Ahearn; L, Bracoud; K, Shamsi; K, Marek; J, Seibyl; G, Riedel; JMD, Storey; CR, Harrington; CM, Wischik

doi:10.3233/jad-170560

Public

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Shared by NobleBlocks on Jan 1, 2018 • 12:00 AM UTC

Authors:

Wilcock GK

Gauthier S

Frisoni GB

Abstract

Background LMTM is being developed as a treatment for AD based on inhibition of tau aggregation.Objectives To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD.Methods Mild AD patients (n = 800) were r...

Subject

tau Protein

Treatment

Alzheimer’s disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!